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Summary 
The rapid and cost-effective identification of bacterial species is crucial, especially for 
clinical diagnosis and treatment. Peptide aptamers have been shown to be valuable for use 
as a component of novel, direct detection methods. These small peptides have a number 
of advantages over antibodies, including greater specificity and longer shelf life. These 
properties facilitate their use as the detector components of biosensor devices. However, 
the identification of suitable aptamer targets for particular groups of organisms is 
challenging. We present a semi-automated processing pipeline for the identification of 
candidate aptamer targets from whole bacterial genome sequences. The pipeline can be 
configured to search for protein sequence fragments that uniquely identify a set of strains 
of interest. The system is also capable of identifying additional organisms that may be of 
interest due to their possession of protein fragments in common with the initial set.  
Through the use of Cloud computing technology and distributed databases, our system is 
capable of scaling with the rapidly growing genome repositories, and consequently of 
keeping the resulting data sets up-to-date. The system described is also more generically 
applicable to the discovery of specific targets for other diagnostic approaches such as 
DNA probes, PCR primers and antibodies.  
1 Introduction 
The detection of a specific bacterial strain or group of related strains is important in many 
industrial and clinical settings.  For example, in the food industry, early detection of the 
presence of organisms such as Salmonella is needed to prevent contamination [1]. Rapid 
diagnostic testing is also necessary for the effective detection and treatment of nosocomial or 
community-acquired infection [2, 3]. Current detection and identification techniques include 
culture isolation, immunoassays and PCR analyses, but these approaches are expensive and 
time consuming [4], and most require specialised laboratory facilities. Consequently, these 
diagnostic tests are of little value for point-of-care screening.  
An increasingly attractive alternative to the use of antibodies for the rapid identification of 
bacterial groups is the use of small molecules, known as aptamers [5]. Aptamers may consist 
of DNA, RNA, XNA or peptide sequences. Peptide aptamers are particularly promising 
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because they are relatively easy to construct and handle, and have the ability to bind to 
proteins with high specificity. 
Peptide aptamers consist of a variable peptidic region that is fused at both termini to a 
scaffold protein [6]. This double fusion limits the conformational liberty of the variable 
region, increasing the specificity and binding affinity of the aptamer [7]. There is currently 
considerable interest in developing rapid diagnostic tests which incorporate aptamers to 
recognise specific molecules. Whilst peptide aptamers typically have specificities similar to 
antibodies, aptamers have a number of advantages that make them amenable to biosensor 
applications [8, 9]. The small size of aptamers, typically 20 to 30 amino acids, enables them 
to reach targets that antibodies may be too large to access [7]. Also, once identified, the highly 
stable aptamers can be synthesised quickly and cheaply [5]. The high binding specificity of 
aptamers enables accurate and immediate detection of specific target proteins [10-12]. 
In order to utilise an aptamer-based sensor, suitable protein targets, or parts of protein targets, 
must first be identified. A target protein or protein region must be unique to the organism or 
group of organisms to be detected. For rapid screening it is important that pre-processing of 
the samples is kept to a minimum. For this reason, the choice of potential target proteins 
residing in or extending from the cell envelope are the most useful targets, since disruption of 
the cells in not necessary and the ligands may be used in surface capture-based strategies. 
Surface-located bacterial proteins are involved in a variety of processes, including host cell 
targeting, immune evasion, mobility and cell wall metabolism [13]. Surface proteins are also 
known to facilitate pathogenicity by imparting drug resistance, and are therefore potential 
candidates for aptamer sensors designed to screen for drug-resistant strains [14, 15]. 
Recently, the amount of DNA and protein sequence data that is freely available in public 
databases has grown exponentially. Therefore, a computational approach employing a 
comparative genomics strategy is now ideally suited for discovering small regions of proteins 
that are displayed at or near the surface of a cell and are conserved only among members of a 
defined group of organisms.  However, the computational demands of such an approach are 
immense, given the scale of the data. Recent advances in Grid and Cloud technologies have 
enabled researchers to access large amounts of computational capacity. Institution-wide 
Condor [16] installations and commercial services such as Amazon EC2
†
 allow access to the 
processing capacity of many hundreds or thousands of machines, real or virtual. Meanwhile 
replicated, distributed data stores can utilise the disk and processing resources of several 
servers simultaneously in order to facilitate the structured storage of billions of data items. 
In the work described here, we made use of the large amounts of genomic and proteomic data 
available in bioinformatics databases, in combination with Cloud computing technology, to 
discover targets suitable for the detection of bacteria using novel sensor technologies.  
Determining suitable diagnostic targets involves a number of steps, which typically form an 
iterative cycle: a) defining the organism or group of organisms to be detected; referred to here 
as the group of interest (GOI); b) finding proteins or protein regions that are unique to a GOI; 
c) determining whether these regions are likely to be surface-accessible; d) assessing whether 
the structure of the protein is likely to allow an aptamer to bind at the target region(s).   
This cycle of steps is typically carried out using a manual approach in which the human user 
needs to access a variety of information sources, databases and bioinformatics tools. 
However, given the number of DNA sequences now in the public domain it is no longer 
possible to carry out the process manually in a systematic and time-efficient manner. Our 
motivation for this work was the creation of a cloud computing system, ApID, that would 
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perform parts (b) and (c) in an automated fashion, through the creation of workflows, thereby 
significantly reducing the number of potential aptamer targets while increasing their 
specificity, and consequently the amount of manual work required in part (d).  
We employed a number of bioinformatics applications, including the Cloud computing 
platform Microbase [17], to develop an automated workflows on which ApID is based. ApID 
has been designed to identify proteins, or small regions of protein sequences, that are unique 
to specific groups of organisms. The protein sequence regions identified by ApID are 
potential aptamer targets since they are common to the defined organisms, but are otherwise 
globally unique. We demonstrate the utility of the system by identifying aptamer targets 
unique to the opportunist pathogen, methicillin resistant Staphylococcus aureus (MRSA).  
2 Methods 
The workflows developed for this work made use of the Microbase Cloud computing 
platform. Microbase is a distributed computing platform that permits the construction of 
bioinformatics workflows from modular components. Microbase consists of a file storage 
system, a publish-subscribe messaging system and a distributed job scheduler. Components, 
termed responders, may be activated on receipt of a particular type of event, such as the entry 
of new data items into the system. Responders can be connected to form a workflow. Each 
responder is responsible for performing one task, such as executing an analysis application 
and managing the resulting data. Actions within a Microbase pipeline are driven by events. 
For example, the addition of new genome data to a database produces a notification event. 
The resulting message is then propagated to further responders that are registered to receive 
this type of message.  
A Microbase pipeline may be highly parallel. Responders can be run in parallel, and each 
responder may generate multiple tasks, each of which, in turn, can run in parallel. For 
example, a number of independent BLAST tasks may be executed at the same time as a set of 
protein subcellular localisation prediction tools. The Microbase system, together with 
responder-specific configuration parameters, determines the exact number of tasks needed, 
and the computers on which they execute analysis tools or maintain databases of results. Each 
workflow component was written in Java and executed on a local 48-core cluster, as well as a 
number of remote Amazon Web Services machines. Microbase managed the distribution and 
execution of tasks over all the available machines.  
The source data used as input to the workflows came from NCBI RefSeq release 47 
(2011/05). RefSeq entries for all available bacteria were parsed and stored in a relational 
database. Result data generated by the workflow was stored in a separate set of PostgreSQL 
databases. These databases were replicated across a number of high performance machines in 
order to increase query performance. 
3 Results 
We developed two automated workflows that form the core of ApID. The first workflow, 
ApID1, performs data integration and storage, bringing together genomic information 
including DNA and protein sequences, predictions about protein cellular location and 
metadata relating to the source of these sequences. A second workflow, ApID2, is then used 
to query the integrated dataset for surface-located protein sequence fragments that are 
globally unique to a particular organismal group of interest (GOI). 
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3.1 Dataset integration and construction workflow (ApID1) 
The 'integration and construction' workflow, ApID1 builds the integrated datasets over which 
ApID2 operates for querying.  The dataset construction phase builds upon the output of a 
number of existing bioinformatics tools. Such tools often operate over independent units of 
data (jobs), and can therefore be executed in an ‘embarrassingly parallel’ [18] fashion. ApID1 
consists of a series of responders that perform the following automated functions: parsing of 
genome information into a structured database; constructing a protein token database that 
covers all protein sequences present in the genome database; and the execution of several 
tools which predict the sub-cellular location of a protein  (Figure 1). These protein tokens 
form the putative target binding regions for the development of diagnostic aptamers.  
A set of GenBank-formatted files was used as the primary data source for the data generation 
pipeline. For this project all of the bacterial genome data from the NCBI RefSeq [19] 
(accessed 05/2011) was downloaded, parsed and stored in a structured data store, the Genome 
Pool Database (GPDB). This relational database allows efficient querying over the RefSeq 
data, and is used extensively by subsequent workflow components.  
 
Figure 1:  The integration and dataset generation pipeline, ApID1. NCBI GenBank-format files 
are inserted, parsed and indexed into a database (the GenomePool). This process triggers the 
execution of a number of analytical tasks that run in parallel: the tokenization of each protein 
sequence and the sub-cellular localization analysis of each protein. This upstream pipeline is 
used to generate several datasets that form the basis for further token analysis. 
The arrival of a new GenBank fragment into the GPDB triggers the 'protein tokeniser' 
responder. This pipeline component iterates over all of the protein sequences in the newly 
added genome fragment. A sliding window is passed over each protein sequence. A token size 
of 15 amino acids was used with a step size of 1, generating a large number of 15-mers for 
each protein sequence (Figure 2). The resulting database, TokenDB, stores the set of 
individual token strings found across all organisms, together with an index to the taxon, 
protein identifier and intra-protein location for every occurrence of every token string. The 
tokenisation work was split into Microbase compute jobs; the scope of each job was a single 
genome fragment, with sizes ranging from a plasmid up to a complete bacterial sequence. 
NCBI GenBank 
files
'New 
genome 
data' 
message
Genome Pool 
responder
LipoP 
responder
TokenDB 
responder
TokenDB
Microbase 
job(s)
'New 
TokenDB 
data' 
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Genome
Pool DB
Microbase 
job(s)
'Genome 
parsed' 
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SignalP 
responder
SignalP 
result DB
Microbase 
job(s)
'New 
SignalP 
data' 
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LipoP 
result DB
Microbase 
job(s)
'New 
LipoP 
data' 
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 Figure 2: Generating the protein token database. The individual protein sequences in a GenBank 
entry are first split into a series of overlapping fragments (tokens). The details of each token, 
including the position within a particular protein and the taxon from which that protein is 
derived are then recorded in a database. The tokens are used to specify the binding sites for 
diagnostic aptamers. 
In addition to triggering protein tokenisation tasks, the addition of a new GenBank fragment 
to the GPDB also triggers the execution of protein sub-cellular localisation tools. TMHMM 
[20] and SignalP [21] were used to determine which proteins are likely to be surface-
associated. Sub-cellular localisation predictions for each protein are stored for future 
querying. An initial set of 3.7 million bacterial proteins from ~1400 organisms   from RefSeq 
generated 1,349,601,310 tokens. Of these, 888,314,351 tokens were unique. 
3.2 Identifying candidate aptamer targets (ApID2) 
Once the integrated dataset has been constructed via ApID1, queries can be performed to 
identify protein sequences, or regions of protein sequences in the form of tokens, that are 
putative target sequences for a target group of interest (GOI). The process of discovering a 
putative aptamer targets consists of a number of stages. These stages are defined in the second 
workflow, the GOI query workflow, ApID2 (Figure 3). 
3.2.1 Groups of Interest 
Firstly, a GOI must be defined. A GOI consists of a set of taxon identifiers that indicate the 
organisms that the diagnostic system must be able to distinguish from the background set. The 
specification of a clearly defined group of organisms is critically important, and defining an 
optimal GOI is a particularly challenging task. Members of a GOI are typically selected 
according to user-specified phenotypic features that are unique to a set of organisms. Finding 
suitable features for diagnostics is problematic for at least two reasons. Firstly, the literature is 
sometimes ambiguous with regard to the phenotypes of a given bacterial species, and there is 
no complete reference database of phenotypes for all bacterial species. Secondly, the species 
concept in bacteria is not well defined, and often phenotypic traits that appear to be attractive 
targets for diagnostics are not encoded by genes that are maintained by orthologous 
mechanisms; many of these genes may be acquired through horizontal gene transfer. 
Therefore, care is needed when selecting candidates for a GOI. If an identified GOI omits 
organisms with the phenotypic feature of interest the results of the query workflow will be 
vastly reduced; many potential protein token results will be 'cancelled out' by the sequences of 
the omitted organism. Conversely, the inclusion in the GOI of even one taxon that does not 
possess the property of interest reduces the probability that unique tokens will be found. 
 
MMTLQIHTGGINLKK
MMTLQIHTGGINLKKKNIYSIRKLGVGIASVTLGTLLISGGVTPAANAAQHDEAQQNAFY
MTLQIHTGGINLKKK
TLQIHTGGINLKKKN
LQIHTGGINLKKKNI
QIHTGGINLKKKNIY
...
A sliding window moves across a protein sequence, 
advancing one amino acid at a time, generating a large 
number of token strings
Token DB
Distinct token strings are assigned an 
identifier and stored in a database. 
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 Figure 3:  The GOI query workflow, ApID2, uses the datasets provided by the automated token 
generation and characterisation workflow, ApID1. A Group of Interest (GOI) is defined, based 
on the phenotype of a set of organisms of interest in a diagnostic context. The TokenDB is 
queried for any fragments of proteins that occur in all organisms defined in the GOI, but which 
do not occur in any other organism present in the NCBI RefSeq dataset. The parent proteins of 
this set of tokens are then identified. Any token that originates in a protein sequence that is not 
predicted to be located on the membrane or cell wall is excluded. Finally, BLAST-P is used to 
verify the remaining tokens against the NCBI’s non-redundant (NR) database. 
 
 
 
Figure 4: A heatmap showing the distribution of tokens around a Group of Interest.  Each cell 
contains a count of unique diagnostic token strings found by adding or removing organisms from 
the initial GOI. In this figure, a peak can be seen when 2 extra organisms are added and one of 
the existing organisms is removed from the original GOI definition. Such a huge increase in 
tokens may indicate that the original GOI was incorrect, especially if most of the additional 
tokens found at 2, 1 are from the same two additional organisms.  
The establishment of a GOI is therefore an iterative process with a biological domain expert 
making an initial GOI prediction that may need to be adjusted in the light of available 
diagnostic signatures. In order to address this uncertainty, the ApID2 workflow provides 
information allowing a user to explore the ‘token space’ around a particular group of interest. 
This functionality allows the user to refine GOI membership through the identification of 
particular strains that may need to be added or removed from a group. To aid this process a 
heat map is constructed representing the total numbers of tokens that occur at each possible 
Dataset construction workflow GOI query workflow
NCBI GenBank 
files
SCL 
prediction 
tools
SignalP
LipoP
PSORTb
Protein Token 
Database
TokenDB
Genome Pool
GPDB
Find set of protein 
tokens unique to all 
organisms
Define GOI
e.g., all Staphylococcus
Filter tokens that do not 
belong to predicted cell 
membrane or wall 
proteins
Screen remaining 
tokens against NR 
BLAST database to 
ensure uniqueness
Output: putative set of surface 
protein fragments unique to all 
members of the defined GOI
Workflow implemented with Microbase and executing on Amazon EC2
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combination of additional or missing taxa with respect to the GOI (Fig.4).  Examination of the 
results with non-zero values for ‘additional’ and ‘missing’ taxa allows the investigator to 
explore outside of the initial GOI space, by adding taxa to or subtracting taxa from the GOI. 
For example, if the number of truly unique tokens for a given GOI is relatively small, but a 
large number of tokens are found when one additional taxon is allowed into the group, then 
this indicates that the GOI might need to be redefined. Specifically, it indicates that an 
organism might be missing from the original GOI defined by the user. 
3.2.2 Token querying and merging 
Once a suitable GOI has been established the purpose of the ApID2 query workflow is to find 
a set of protein tokens that exist in all of the members of the GOI, but that do not exist in any 
other organism present in the database. We refer to these tokens as being globally unique to a 
particular version of the integrated dataset.  
A list of token fragments that are unique to the organisms in the GOI is  obtained first. The 
length of this list depends on the number of organisms in the GOI and the extent of their 
diversity. Typically, a list consists of several million items. All of the token strings in this list 
occur at least once in one or more members of the GOI. Each token string must then be 
queried against the entire token database in order to determine in which other proteins it 
occurs.  This step can be performed in a parallel manner if a cluster of database machines is 
used, but is still a computational bottleneck. If the taxon IDs associated with the proteins 
returned from each token string query exactly match the set of taxon IDs present in the GOI, 
then the token string can be considered globally unique to all of the organisms in the GOI. 
In many cases, regions larger than a 15-mer token may be common to the members of a GOI, 
for example when part of a protein is conserved among all organisms in the group. In these 
cases, it is desirable to merge consecutive, overlapping tokens together into ‘super tokens’ in 
order to reduce the analysis workloads and storage space. Variable length unique super 
tokens, rather than the original 15-mer tokens, are used for the remainder of the sequence 
selection process.  
Whilst each super token is globally unique to the set of organisms in a GOI, it is also desirable 
to identify sequences similar, but not identical to super tokens in the next closest sequence 
outside of the GOI. This procedure is necessary since it is possible that an aptamer may be 
tolerant of mismatches in its target sequence, leading to false positive hits with respect to a 
given GOI. Furthermore, other ligand-based diagnostics such as antibodies can also be 
tolerant of amino-acid changes in their epitopes. Therefore, the next stage of the ApID2 
workflows involves performing a BLAST similarity search of each super token against the 
NCBI’s non-redundant (NR) database. The super tokens with high similarity to regions of 
proteins belonging to organisms outside the GOI are discarded.  
The final stage of the selection process involves ranking the tokens by the likelihood that they 
are accessible on the surface of the cell. The predictions from various sub-cellular localisation 
tools are used to annotate the super-token fragments with tags that indicate whether a 
particular fragment might be localised on the surface of the cell. These annotations can be 
visualised within a graphical viewer to browse the available super tokens and either filter or 
sort them according to the presence or absence of a tag, or the score of a subcellular 
localisation prediction tool. Intermediate results are stored throughout the selection process, 
allowing manual inspection and intervention at any point in the pipeline. Once identified, 
tokens are verified using a series of manual bioinformatics analysis. These analytical steps 
include verification using a variety of sequence searches against the databases (Blast, FastA 
etc.), phylogenetic analysis, and the mapping of tokens onto a protein structure, or predicted 
protein structure, in order to verify that an identified token is actually surface-accessible.  
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3.3 Use case: Application of ApID to the design of aptamers for the 
detection of methicillin-resistant Staphylococcus aureus.  
The ApID system described above was used to find tokens acting as putative targets for 
Aptamers that would bind uniquely to methicillin-resistant staphylococci. Firstly, a list of all 
staphylococci with genome sequences in RefSeq (as of 2011/05), together with their 
methicillin resistance status, was gathered from the literature (Table 1). We then defined a 
number of GOIs based on the drug resistance information available for the various strains 
listed in Table 1, and these GOIs were processed by the ApID2 pipeline (Table 2). Three 
GOIs were identified. Taxon group (a) consists of all Staphylococcus proteomes identified as 
finished in RefSeq. In this GOI, just 22 proteins (one per taxon) had a positive SpII Lipop 
prediction indicating surface localisation.  A large number of membrane-associated proteins 
were predicted using both psortb and TmHMM. Taxon group (b) consists of just the 
Staphylococcus aureus strains. As expected when comparing a set of more closely related 
strains, a much larger set of unique token strings was found. On average, in this group, 1900 
proteins from each strain shared at least one distinct token string. Many more cell membrane 
and cell wall proteins were predicted to be suitable aptamer targets. Furthermore, many more 
Lipop SpII predictions are present in GOI (b) than in group (a), and psortb predicted 
427 cell wall proteins. 
Table 1: A summary of the known methicillin resistance/sensitivity of the Staphylococcal strains 
whose genomes are available in the NCBI RefSeq database.  A value of ‘ambiguous’ in the 
‘resistance’ column means that the literature is contradictory; ‘unknown’ indicates that no 
information about methicillin resistance could be found for a particular strain. 
Strain RefSeq  
Taxon ID 
Resistant to 
methicillin 
Reference 
Staphylococcus aureus RF122  273036 No [22] 
Staphylococcus aureus subsp. aureus COL 93062 Yes [23] 
Staphylococcus aureus subsp. aureus ED98  681288 No [22] 
Staphylococcus aureus subsp. aureus JH1 359787 Yes [22] 
Staphylococcus aureus subsp. aureus JH9 359786 Yes [24] 
Staphylococcus aureus subsp. aureus MRSA252 282458 Yes [23]. 
Staphylococcus aureus subsp. aureus MSSA476 282459 No [23] 
Staphylococcus aureus subsp. aureus Mu3 418127 Yes [24] 
Staphylococcus aureus subsp. aureus Mu50 158878 Yes [23] 
Staphylococcus aureus subsp. aureus MW2 196620 Yes [23]. 
Staphylococcus aureus subsp. aureus N315 158879 Yes [23] 
Staphylococcus aureus subsp. aureus NCTC 8325 93061 No [23] 
Staphylococcus aureus subsp. aureus str. Newman 426430 No [22] 
Staphylococcus aureus subsp. aureus USA300_FPR3757 451515 Yes [25, 26] 
Staphylococcus aureus subsp. aureus USA300_TCH1516 451516 Yes [26, 27] 
Staphylococcus carnosus subsp. carnosus TM300 396513 No [28, 29] 
Staphylococcus epidermidis ATCC 12228 176280 Ambiguous [30, 31] 
Staphylococcus epidermidis RP62A  176279 Yes [32] 
Staphylococcus haemolyticus JCSC1435 279808 Yes [31] 
Staphylococcus lugdunensis HKU09-01 698737 Unknown  
Staphylococcus pseudintermedius HKU10-03 937773 Unknown  
Staphylococcus saprophyticus subsp. saprophyticus ATCC 15305 342451 Unknown  
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Group (c) was defined based on all Staphylococcus strains for which any evidence of 
resistance to methicillin was found (Table 1). Only 12 distinct token strings were found, a 
figure much lower than might be expected. These tokens were located in a single conserved 
uncharacterised protein, SACOL0037. An investigation of the token space around this GOI 
was carried out to shed light on the reason for this reduced number of tokens (Figure 5). An 
analysis of the number of distinct tokens contributed by each strain in a leave one out strategy 
revealed that Staphylococcus epidermidis ATCC 12228 is an outlier to the group. In this 
strategy, sub-GOIs are created by systematically leaving out one member of the group at a 
time and counting the number of unique tokens available for that subgroup. Strains whose 
inclusion results in a major reduction of the unique tokens are highlighted as warranting 
further investigation into the validity of their inclusion in the GOI. The leave-one-out exercise 
resulted in the identification of approximately 1,000 distinct tokens contributed by each strain 
considered, except for S. aureus ATCC12228, which provided almost no new tokens. This 
finding indicates that ATCC12228 may not belong in the original GOI. 
With the above results in mind, a further GOI, (d), was defined consisting of any 
Staphylococcus strain for which evidence of methicillin resistance exists (same as group c), 
but with the exclusion of strain Staphylococcus epidermidis ATCC 12228. This strain was 
excluded from group (d) because of conflicting reports about its resistance to methicillin [30, 
31].  This grouping resulted in the prediction of many more distinct tokens (993) from four 
different sets of homologous proteins.  None of these proteins were predicted to possess signal 
peptides, and none were predicted to be cell wall associated. Twelve proteins, one per 
organism, were predicted to be membrane associated. This group of 12 was comprised of 
orthologous members of the well-known penicillin-binding protein 2’, MecA family, 
SACOL0033. The only other proteins identified in group (d) were MaoC (SACOL0032), 
IS431mec (transposase) (SACOL0028), and glycerophosphoryl diester phosphodiesterase 
(SACOL0031). The details of the various GOIs are listed in Table 2.  
Table 2: A number of groups of interest (GOIs) were defined (a-d), which were analysed by the 
analysis pipeline. The number of distinct tokens for each group is shown, together with a 
summary from various SCL prediction tools for the set of proteins for which at least one distinct 
token string was present. The GOIs were: a) a group containing all organisms listed in Table 1; 
b) a subgroup containing just the S. aureus strains; c) a subgroup containing organisms for 
which any evidence of methicillin resistance existed; d) an alternative methicillin resistance 
group, excluding the ATCC 2228 strain that Takeuchi et al report as methicillin-sensitive. 
 GOI 
 (a) (b) (c) (d) 
No. organisms 22 15 13 12 
No. group-unique token 
occurrences 
97,995 4,625,838 192 11,976 
Distinct group-unique token 
strings 
4,438 307,102 12 993 
No. proteins containing at 
least one GOI-unique token 
instance 
10,115 28,593 
17 (1 set of 
homologues) 
52 (4 sets of 
homologues) 
SignalP positive predictions 113 1,926 0 0 
LipoP SpII positive 
predictions 
22 829 0 0 
psortb predictions 
(Membrane / Wall) 
1935 / 22 7791 / 427 
0 / 0 (all 
‘unknown’) 
12 / 0 
TmHMM (proteins with > 0 
transmembrane domains) 
1730 7761 0 12 
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3.4 Conclusions and future work 
As the utility, range and popularity of molecular diagnostics increases, databases of bacterial 
genome sequences will become an increasingly valuable resource. In this work, we 
demonstrate how the mining of bacterial genome sequences can be used to design target 
protein sequences for diagnostic protein aptamers, using the ApID system. Whilst the work 
we present is specific for protein aptamers, the approach is more generically applicable to any 
ligand-based diagnostic system where a unique protein sequence target may be used to design 
an epitope. These systems include antibodies, antibody fragments and, by replacing protein 
sequences with their encoding DNA sequence, DNA and RNA probes.  
We show how the system can be used to specify targets for aptamers specific for methicillin 
Staphylococcus aureus. Aptamers targeting these sequences are being characterised in our 
laboratory. The ApID system is generically applicable for finding diagnostic protein 
signatures for a range of applications of relevance to medical care, the food industry and to 
the environment.  
A major requirement of ApID is that the user is able to define a GOI that includes the 
organisms they would like to detect. The definition of a GOI is a challenging exercise, 
requiring a combination of user expertise, information about the phenotypic traits of 
organisms from the literature and databases, and a clear definition of bacterial species. 
Sources of information relating to these requirements are often prone to error, and the species 
defined by classical numeric taxonomy frequently do not correlate exactly with those defined 
through similarity at the genome sequence level. The ApID system therefore allows a user to 
suggest a GOI and then explore the effect, on the number of unique tokens generated, of 
modifying the group membership, thus optimising the GOI. In the future it may be possible 
automatically predefine suggested groups of interest based on the occurrence of shared 
tokens, saving time by avoiding the need for the dynamic execution of the ApID2 workflow.  
A major challenge of the approach implemented in the ApID system is the computationally 
intensive nature of both the preparation of the integrated datasets and data mining for tokens 
for a given GOI. Here, we show how the combined use of Cloud computing workflows and 
parallel databases can be used to address this challenge. We used a system previously 
constructed in our group, Microbase, to implement the two major workflows underlying the 
ApID system. Microbase automatically handles the issues of task scheduling, parallelisation 
and job monitoring and execution. The use of the tokenisation strategy allows a fine-grained 
definition of diagnostic targets but also adds a layer computational demand. We address this 
demand through the use of a high performance cluster of replicated databases.  
The use of a Cloud-based approach allows the system to be scaled with the number of 
complete bacterial genome sequences, which continues to increase in an exponential fashion. 
Furthermore, the use of workflows and the Microbase system allows much of the system to be 
automated, automatically executing workflows as the databases are updated. In the future we 
envisage that the system will be enhanced to further exploit the increasingly large number of 
incomplete genomic sequences that are accumulating in the sequence databases.  
Acknowledgements 
We would like to acknowledge the assistance of the Newcastle University Bioinformatics 
Support Unit. This work was supported by EPSRC project EP/G061394/1.  
 
Journal of Integrative Bioinformatics, 11(2):242, 2014 http://journal.imbio.de
doi:10.2390/biecoll-jib-2014-242 10
C
op
yr
ig
ht
 2
01
4 
Th
e 
A
ut
ho
r(
s)
. P
ub
lis
he
d 
by
 J
ou
rn
al
 o
f I
nt
eg
ra
tiv
e 
B
io
in
fo
rm
at
ic
s.
 
Th
is
 a
rti
cl
e 
is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
-N
oD
er
iv
s 
3.
0 
U
np
or
te
d 
Li
ce
ns
e 
(h
ttp
://
cr
ea
tiv
ec
om
m
on
s.
or
g/
lic
en
se
s/
by
-n
c-
nd
/3
.0
/).
Brought to you by | Newcastle University
Authenticated
Download Date | 8/29/17 3:39 PM
References 
[1] M. Taban, S. Aytac, N. Akkoc, and M. Akcelik. Characterization of antibiotic 
resistance in Salmonella enterica isolates determined from ready-to-eat (RTE) salad 
vegetables. Brazilian Journal of Microbiology, 44:385 - 391, 2013. 
[2] F. Barbut, L. Surgers, C. Eckert, B. Visseaux, M. Cuingnet, C. Mesquita, N. Pradier, 
A. Thiriez, N. Ait‐Ammar, and A. Aifaoui. Does a rapid diagnosis of Clostridium 
difficile infection impact on quality of patient management? Clinical Microbiology 
and Infection, 20:136-144, 2014. 
[3] O. Clerc, G. Prod'hom, L. Senn, K. Jaton, G. Zanetti, T. Calandra, and G. Greub. 
Matrix‐assisted laser desorption ionization time‐of‐flight mass spectrometry and PCR‐
based rapid diagnosis of Staphylococcus aureus bacteraemia. Clinical Microbiology 
and Infection, 2013. 
[4] H. Noorani, E. Adams, S. Glick, S. Weber, S. Belinson, and N. Aronson. Screening 
for Methicillin-Resistant Staphylococcus aureus (MRSA): Future Research Needs: 
Identification of Future Research Needs From Comparative Effectiveness Review No. 
102 Rockville (MD): Agency for Healthcare Research and Quality (US) Future 
Research Needs Papers, 40:2013. 
[5] K.-M. Song, S. Lee, and C. Ban. Aptamers and their biological applications. Sensors, 
12:612-631, 2012. 
[6] J. Thibaut, Y. Mérieux, D. Rigal, and G. Gillet. A novel assay for the detection of anti-
human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology. 
Haematologica, 97:696-704, 2012. 
[7] I. C. Baines and P. Colas. Peptide aptamers as guides for small-molecule drug 
discovery. Drug Discovery Today, 11:334-341, 2006. 
[8] L. K. J. Stadler, T. Hoffmann, D. C. Tomlinson, Q. Song, T. Lee, M. Busby, Y. 
Nyathi, E. Gendra, C. Tiede, and K. Flanagan. Structure−function studies of an 
engineered scaffold protein derived from Stefin A. II: Development and applications 
of the SQT variant. Protein Engineering Design and Selection, 24:751-763, 2011. 
[9] J.-O. Lee, H.-M. So, E.-K. Jeon, H. Chang, K. Won, and Y. Kim. Aptamers as 
molecular recognition elements for electrical nanobiosensors. Analytical and 
Bioanalytical Chemistry, 390:1023-1032, 2008. 
[10] D. Evans, S. Johnson, S. Laurenson, G. Davies, P. Ko Ferrigno, and C. Walti. 
Electrical protein detection in cell lysates using high-density peptide-aptamer 
microarrays. 
[11] P. Estrela, D. Paul, Q. Song, L. K. J. Stadler, L. Wang, E. Huq, J. J. Davis, P. K. 
Ferrigno, and P. Migliorato. Label-Free Sub-picomolar Protein Detection with Field-
Effect Transistors. Analytical Chemistry, 82:3531-3536, 2010. 
[12] L.-Q. Gu and J. W. Shim. Single molecule sensing by nanopores and nanopore 
devices. Analyst, 135:441-451, 2010. 
[13] W. W. Navarre and O. Schneewind. Surface proteins of gram-positive bacteria and 
mechanisms of their targeting to the cell wall envelope. Microbiology and Molecular 
Biology Reviews, 63:174-229, 1999. 
[14] G. K. Paterson and T. J. Mitchell. The biology of Gram-positive sortase enzymes. 
Trends in Microbiology, 12:89-95, 2004. 
Journal of Integrative Bioinformatics, 11(2):242, 2014 http://journal.imbio.de
doi:10.2390/biecoll-jib-2014-242 11
C
op
yr
ig
ht
 2
01
4 
Th
e 
A
ut
ho
r(
s)
. P
ub
lis
he
d 
by
 J
ou
rn
al
 o
f I
nt
eg
ra
tiv
e 
B
io
in
fo
rm
at
ic
s.
 
Th
is
 a
rti
cl
e 
is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
-N
oD
er
iv
s 
3.
0 
U
np
or
te
d 
Li
ce
ns
e 
(h
ttp
://
cr
ea
tiv
ec
om
m
on
s.
or
g/
lic
en
se
s/
by
-n
c-
nd
/3
.0
/).
Brought to you by | Newcastle University
Authenticated
Download Date | 8/29/17 3:39 PM
[15] A. M. Edwards, J. R. Potts, E. Josefsson, and R. C. Massey. Staphylococcus aureus 
host cell invasion and virulence in sepsis is facilitated by the multiple repeats within 
FnBPA. PLoS Pathogens, 6:e1000964, 2010. 
[16] M. J. Litzkow, M. Livny, and M. W. Mutka. Condor-a hunter of idle workstations. in 
Distributed Computing Systems, 1988., 8th International Conference on, 1988, pp. 
104-111. 
[17] K. Flanagan, S. Nakjang, J. Hallinan, C. Harwood, R. P. Hirt, M. R. Pocock, and A. 
Wipat. Microbase2.0: A generic framework for computationally intensive 
bioinformatics workflows in the cloud. presented at the 2012 International Symposium 
on Integrative Bioinformatics (IB2012), Hangzhou, China, 2012. 
[18] C. Moler. Matrix Computation on Distributed Memory Multiprocessors. Philadelphia: 
Society for Industrial and Applied Mathematics, 1986. 
[19] K. D. Pruitt, T. Tatusova, G. R. Brown, and D. R. Maglott. NCBI Reference 
Sequences (RefSeq): current status, new features and genome annotation policy. 
Nucleic Acids Research, 40:D130-D135, 2012. 
[20] A. Krogh, B. Larsson, G. Von Heijne, and E. L. Sonnhammer. Predicting 
transmembrane protein topology with a hidden Markov model: application to 
complete genomes. Journal of Molecular Biology, 305:567-580, 2001. 
[21] T. N. Petersen, S. Brunak, G. von Heijne, and H. Nielsen. SignalP 4.0: Discriminating 
signal peptides from transmembrane regions. Nature Methods, 8:785-786, 2011. 
[22] H. Xue, H. Lu, and X. Zhao. Sequence diversities of serine-aspartate repeat genes 
among Staphylococcus aureus isolates from different hosts presumably by horizontal 
gene transfer. PLoS ONE, 6:e20332:2011. 
[23] K. Hardy, D. Ussery, B. Oppenheim, and P. Hawkey. Distribution and characterization 
of staphylococcal interspersed repeat units (SIRUs) and potential use for strain 
differentiation. Microbiology, 150:4045-4052, 2004. 
[24] I. A. Al-Zahrani, C. Hamson, D. Edge, J. Collins, J. D. Perry, M. Raza, G. K., and C. 
R. Harwood. A SmaI restriction site-based multiplex PCR for  typing of hospital and 
community acquired Staphylococcus aureus. Journal of Clinical Microbiology, 
49:3820-3828, 2011. 
[25] B. A. Diep, S. R. Gill, R. F. Chang, T. H. Phan, J. H. Chen, M. G. Davidson, F. Lin, J. 
Lin, H. A. Carleton, and E. F. Mongodin. Complete genome sequence of USA300, an 
epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. 
The Lancet, 367:731-739, 2006. 
[26] S. K. Highlander, K. G. Hultén, X. Qin, H. Jiang, S. Yerrapragada, E. O. Mason, Y. 
Shang, T. M. Williams, R. M. Fortunov, and Y. Liu. Subtle genetic changes enhance 
virulence of methicillin resistant and sensitive Staphylococcus aureus. BMC 
Microbiology, 7:99, 2007. 
[27] K. Nicolaou, N. L. Simmons, J. S. Chen, N. M. Haste, and V. Nizet. Total synthesis 
and biological evaluation of marinopyrrole A and analogs. Tetrahedron Letters, 
52:2041-2043, 2011. 
[28] W. Tesch, A. Strässle, B. Berger-Bächi, D. O'Hara, P. Reynolds, and F. Kayser. 
Cloning and expression of methicillin resistance from Staphylococcus epidermidis in 
Staphylococcus carnosus. Antimicrobial Agents and Chemotherapy, 32:1494-1499, 
1988. 
Journal of Integrative Bioinformatics, 11(2):242, 2014 http://journal.imbio.de
doi:10.2390/biecoll-jib-2014-242 12
C
op
yr
ig
ht
 2
01
4 
Th
e 
A
ut
ho
r(
s)
. P
ub
lis
he
d 
by
 J
ou
rn
al
 o
f I
nt
eg
ra
tiv
e 
B
io
in
fo
rm
at
ic
s.
 
Th
is
 a
rti
cl
e 
is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
-N
oD
er
iv
s 
3.
0 
U
np
or
te
d 
Li
ce
ns
e 
(h
ttp
://
cr
ea
tiv
ec
om
m
on
s.
or
g/
lic
en
se
s/
by
-n
c-
nd
/3
.0
/).
Brought to you by | Newcastle University
Authenticated
Download Date | 8/29/17 3:39 PM
[29] R. Rosenstein, C. Nerz, L. Biswas, A. Resch, G. Raddatz, S. C. Schuster, and F. Götz. 
Genome analysis of the meat starter culture bacterium Staphylococcus carnosus 
TM300. Applied and Environmental Microbiology, 75:811-822, 2009. 
[30] Y. Q. Zhang, S. X. Ren, H. L. Li, Y. X. Wang, G. Fu, J. Yang, Z. Q. Qin, Y. G. Miao, 
W. Y. Wang, and R. S. Chen. Genome‐based analysis of virulence genes in a non‐
biofilm‐forming Staphylococcus epidermidis strain (ATCC 12228). Molecular 
Microbiology, 49:1577-1593, 2003. 
[31] F. Takeuchi, S. Watanabe, T. Baba, H. Yuzawa, T. Ito, Y. Morimoto, M. Kuroda, L. 
Cui, M. Takahashi, and A. Ankai. Whole-genome sequencing of Staphylococcus 
haemolyticus uncovers the extreme plasticity of its genome and the evolution of 
human-colonizing staphylococcal species. Journal of Bacteriology, 187:7292-7308, 
2005. 
[32] S. R. Gill, D. E. Fouts, G. L. Archer, E. F. Mongodin, R. T. DeBoy, J. Ravel, I. T. 
Paulsen, J. F. Kolonay, L. Brinkac, and M. Beanan. Insights on evolution of virulence 
and resistance from the complete genome analysis of an early methicillin-resistant 
Staphylococcus aureus strain and a biofilm-producing methicillin-resistant 
Staphylococcus epidermidis strain. Journal of Bacteriology, 187:2426-2438, 2005. 
 
Journal of Integrative Bioinformatics, 11(2):242, 2014 http://journal.imbio.de
doi:10.2390/biecoll-jib-2014-242 13
C
op
yr
ig
ht
 2
01
4 
Th
e 
A
ut
ho
r(
s)
. P
ub
lis
he
d 
by
 J
ou
rn
al
 o
f I
nt
eg
ra
tiv
e 
B
io
in
fo
rm
at
ic
s.
 
Th
is
 a
rti
cl
e 
is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
-N
oD
er
iv
s 
3.
0 
U
np
or
te
d 
Li
ce
ns
e 
(h
ttp
://
cr
ea
tiv
ec
om
m
on
s.
or
g/
lic
en
se
s/
by
-n
c-
nd
/3
.0
/).
Brought to you by | Newcastle University
Authenticated
Download Date | 8/29/17 3:39 PM
